{"entity":{"type":"insider","cik":"0001827326","url":"/insider/0001827326","json_url":"/insider/0001827326.json","name":"Eisele Jeffrey","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":15,"n_filings":13,"first":"2023-01-25","last":"2025-01-30","span_basis":"filed_date"},"name_variants":[{"name":"Eisele Jeffrey","source":"filing","n_filings":13,"first_seen":"2023-01-25","last_seen":"2025-01-30"}],"transactions":[{"id":5084787,"accession":"0001127602-25-002379","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-002379","line_url":"/filing/0001127602-25-002379#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":278.0,"shares_display":"278","price_per_share":29.5236,"price_display":"29.52","price_state":"stated","total_value":8207.5608,"total_display":"8,207.56","total_whole":"8,208","shares_owned_after":55312.0,"shares_owned_after_display":"55,312","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-29","filed_date":"2025-01-30","scope":"insider"},{"id":4630818,"accession":"0001127602-25-001835","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-001835","line_url":"/filing/0001127602-25-001835#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1291.0,"shares_display":"1,291","price_per_share":30.4255,"price_display":"30.43","price_state":"stated","total_value":39279.3205,"total_display":"39,279.32","total_whole":"39,279","shares_owned_after":55590.0,"shares_owned_after_display":"55,590","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":4550541,"accession":"0001127602-25-001193","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-25-001193","line_url":"/filing/0001127602-25-001193#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":264.0,"shares_display":"264","price_per_share":28.7021,"price_display":"28.70","price_state":"stated","total_value":7577.3544,"total_display":"7,577.35","total_whole":"7,577","shares_owned_after":56881.0,"shares_owned_after_display":"56,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-13","filed_date":"2025-01-14","scope":"insider"},{"id":2841565,"accession":"0001127602-24-030106","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-030106","line_url":"/filing/0001127602-24-030106#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63.0,"shares_display":"63","price_per_share":33.09,"price_display":"33.09","price_state":"stated","total_value":2084.67,"total_display":"2,084.67","total_whole":"2,085","shares_owned_after":57145.0,"shares_owned_after_display":"57,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-27","scope":"insider"},{"id":2052384,"accession":"0001127602-24-002738","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-24-002738","line_url":"/filing/0001127602-24-002738#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":971.0,"shares_display":"971","price_per_share":65.53,"price_display":"65.53","price_state":"stated","total_value":63629.63,"total_display":"63,629.63","total_whole":"63,630","shares_owned_after":57208.0,"shares_owned_after_display":"57,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-01-31","scope":"insider"},{"id":2052382,"accession":"0001127602-24-002738","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-002738","line_url":"/filing/0001127602-24-002738#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":279.0,"shares_display":"279","price_per_share":64.1382,"price_display":"64.14","price_state":"stated","total_value":17894.5578,"total_display":"17,894.56","total_whole":"17,895","shares_owned_after":58179.0,"shares_owned_after_display":"58,179","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-29","filed_date":"2024-01-31","scope":"insider"},{"id":2306737,"accession":"0001127602-24-002012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-002012","line_url":"/filing/0001127602-24-002012#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7378.0,"shares_display":"7,378","price_per_share":63.69,"price_display":"63.69","price_state":"stated","total_value":469904.82,"total_display":"469,904.82","total_whole":"469,905","shares_owned_after":58458.0,"shares_owned_after_display":"58,458","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-24","scope":"insider"},{"id":3067594,"accession":"0001127602-24-001943","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-001943","line_url":"/filing/0001127602-24-001943#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1607.0,"shares_display":"1,607","price_per_share":64.996,"price_display":"65.00","price_state":"stated","total_value":104448.572,"total_display":"104,448.57","total_whole":"104,449","shares_owned_after":65836.0,"shares_owned_after_display":"65,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-22","filed_date":"2024-01-23","scope":"insider"},{"id":3154958,"accession":"0001127602-24-001603","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-24-001603","line_url":"/filing/0001127602-24-001603#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5207.0,"shares_display":"5,207","price_per_share":65.58,"price_display":"65.58","price_state":"stated","total_value":341475.06,"total_display":"341,475.06","total_whole":"341,475","shares_owned_after":67443.0,"shares_owned_after_display":"67,443","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-17","filed_date":"2024-01-18","scope":"insider"},{"id":2086685,"accession":"0001127602-24-001380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-24-001380","line_url":"/filing/0001127602-24-001380#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":438.0,"shares_display":"438","price_per_share":66.8086,"price_display":"66.81","price_state":"stated","total_value":29262.1668,"total_display":"29,262.17","total_whole":"29,262","shares_owned_after":72650.0,"shares_owned_after_display":"72,650","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-17","scope":"insider"},{"id":8413892,"accession":"0001127602-23-030552","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001127602-23-030552","line_url":"/filing/0001127602-23-030552#line-2","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":235.0,"shares_display":"235","price_per_share":60.23,"price_display":"60.23","price_state":"stated","total_value":14154.05,"total_display":"14,154.05","total_whole":"14,154","shares_owned_after":53580.0,"shares_owned_after_display":"53,580","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-27","filed_date":"2023-12-28","scope":"insider"},{"id":8413889,"accession":"0001127602-23-030552","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-030552","line_url":"/filing/0001127602-23-030552#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":68.0,"shares_display":"68","price_per_share":57.8609,"price_display":"57.86","price_state":"stated","total_value":3934.5412,"total_display":"3,934.54","total_whole":"3,935","shares_owned_after":53815.0,"shares_owned_after_display":"53,815","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-26","filed_date":"2023-12-28","scope":"insider"},{"id":7861848,"accession":"0001127602-23-007327","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-007327","line_url":"/filing/0001127602-23-007327#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1646.0,"shares_display":"1,646","price_per_share":68.76,"price_display":"68.76","price_state":"stated","total_value":113178.96,"total_display":"113,178.96","total_whole":"113,179","shares_owned_after":53883.0,"shares_owned_after_display":"53,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-23","filed_date":"2023-02-27","scope":"insider"},{"id":8649031,"accession":"0001127602-23-002753","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-002753","line_url":"/filing/0001127602-23-002753#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":883.0,"shares_display":"883","price_per_share":52.76,"price_display":"52.76","price_state":"stated","total_value":46587.08,"total_display":"46,587.08","total_whole":"46,587","shares_owned_after":46468.0,"shares_owned_after_display":"46,468","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-01-31","scope":"insider"},{"id":8586758,"accession":"0001127602-23-002172","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-23-002172","line_url":"/filing/0001127602-23-002172#line-1","is_derivative":false,"issuer_cik":"0001492422","issuer_name":"Apellis Pharmaceuticals, Inc.","issuer_ticker":"APLS","issuer_name_source":null,"issuer_url":"/issuer/0001492422","owner_cik":"0001827326","owner_name":"Eisele Jeffrey","owner_display_name":"Eisele Jeffrey","owner_url":"/insider/0001827326","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4479.0,"shares_display":"4,479","price_per_share":51.58,"price_display":"51.58","price_state":"stated","total_value":231026.82,"total_display":"231,026.82","total_whole":"231,027","shares_owned_after":47718.0,"shares_owned_after_display":"47,718","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-25","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":15,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":15,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":15},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001492422","name":"Apellis Pharmaceuticals, Inc.","url":"/issuer/0001492422","role":"Officer (Chief Development Officer)","n_filings":13,"first_seen":"2023-01-25","last_seen":"2025-01-30"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001827326","retrieved_at":"2026-08-27T05:14:40+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}